STATE OF ALASKA
DEPARTMENT OF COMMERCE, COMMUNITY AND ECONOMIC DEVELOPMENT
DIVISION OF CORPORATIONS, BUSINESS & PROFESSIONAL LICENSING

BOARD OF PHARMACY
MINUTES OF MEETING
May 4-5, 2017

By authority of AS 08.01.070(2) and in compliance with the provisions of Article 6 of AS 44.62, a scheduled teleconference meeting of the Board of Pharmacy was held May 4-5, 2017 at the Atwood Building 550 W7th, Suite 1620.

These minutes were prepared by the staff of the Division of Corporations, Business and Professional Licensing. The minutes have not been reviewed or approved by the Board of Pharmacy.

The meeting was called to order by Chair, Leif Holm at 9:09 a.m.

Call to Order/Roll Call

Board Members Present constituting a quorum:

Leif Holm, PharmD, North Pole – Chair
Richard Holt, PharmD, Wasilla – Vice Chair
Phil Sanders, RPh, Soldotna
Lana Bell, RPh, Anchorage
James Henderson, RPh, Soldotna
Anne Gruening, Public Member, Juneau - Secretary

James Henderson arrived and joined the meeting at 9:11 a.m.
Anne Gruening arrived and joined the meeting at 9:41 a.m.

Attending from the Division of Corporations, Business and Professional Licensing were:

Donna Bellino, Licensing Examiner – Juneau
Brian Howes, Investigator – Anchorage
Sara Chambers, Deputy Director, Juneau – Telephonically

Visitors Present –

Adam Chesler, PharmD. - Director, Regulatory Affairs/ CardinalHealth Telephonically
Alex Kirsonis, Pharmacy Intern – Pioneer Home

Agenda Item 1- Review Agenda

The board reviewed the agenda for Thursday, May 4, 2017.

On a motion duly made by Ms. Bell, seconded by Mr. Holt and approved unanimously, it was

RESOLVED to approve the agenda for Thursday, May 4, 2017.

Agenda Item 2- Review/Adopt Meeting Minutes

The Board reviewed the minutes from the January 13th Teleconference.

On a motion duly made by Ms. Bell, seconded by Mr. Holt and approved unanimously, it was

RESOLVED to approve the minutes from January 13, 2017, Teleconference.

The Board reviewed the minutes from the March 2-3, 2017 Board of Pharmacy Meeting.

On a motion duly made by Mr. Sanders, seconded by Mr. Holm and approved unanimously, it was

RESOLVED to approve the minutes from the March 2-3, 2017, meeting.

Agenda Item 3- Ethics

Mr. Holm called for any ethics disclosures to be made. No ethics violations to report by board or staff.

Agenda Item 4 – Investigative Report – Investigator Howes

Investigator Howes presented the Investigative Report for the period of February 15, 2017 through April 14, 2017. Including cases, complaints, and intake matters, since the last report, the Division opened eight (8) files and closed nine (9) Pharmacy Board matters. A total of Eighteen (18) matters remain on-going and under active investigation or are pending litigation.

Investigator Howes advised the Board there were two cases to be discussed in executive session and he had an update on a Board request to be discussed as well.

On a motion duly made by Mr. Holt, seconded by Ms. Bell and approved unanimously, it was

> **RESOLVED to go into executive session in accordance with AS44.62. 301(c), for purposes of discussing investigative matters.**

Case No. 2016-001037
Case No. 2016-001006

Board staff to remain.

Off the record at 9:31 a.m.
On the record at 10:14 a.m.

9:41 a.m. Ms. Gruening joined the meeting while the Board was in executive session.

Due to the short time left until the budget review the Board decided to stay on track and will vote on the cases discussed after the review.

Agenda Item 5 – Budget Review

Sara Chambers, Deputy Director for the division reviewed the Revenue & Expenditures reports for: FY 17 1st - 3rd Quarters. There were no fiscal questions from the Board.

Ms. Chambers provided a brief legislative update to the Board regarding key bills of interest relating to pharmacy.

The House is holding quite a few senate bills in House rules and not hearing them. The Senate is refusing to hear bills on most topics other than the list that Senate President Kelly has provided.

The opioid issues are one of the topics that the senate president would like the senate to hear testimony on. There is optimism that HB159 will move out of house finance next week and go over to the senate side. This is the Governor's bill on opioids that the pharmacy industry and both Leif Holm and Rich Holt have provided feedback on.

There have been amendments made to this bill in response to feedback received from the Board, the Alaska Pharmacist Association, ASHNA, and others, and is getting a lot of support. This bill has been amended to take in to consideration some of the concerns raised. Of the two opioid bills from the Governor it is anticipated that HB159 would be the bill out of the two governor's opioid bills that would move forward for the rest of this session.

SB32 – *"An Act relating to biological products; relating to the practice of pharmacy; relating to the Board of Pharmacy; and providing for an effective date."*

Director Hovenden attended a hearing on May 3rd in House Finance and it was heard and held. This would be its last stop before the House floor.

SB37/HB9 –*"An Act relating to the Board of Pharmacy; relating to licensing and inspection of certain facilities located outside the state; relating to drug supply chain security; and creating a position of executive administrator for the Board of Pharmacy."*

Important to the Board but both bills are sitting in committee and have not moved forward. If they do not move forward this year these bills will remain active for next year.

HB90 – *"An Act relating to occupational licensing fees; relating to an occupational investigation surcharge; and providing for an effective date."*

This bill is still in the house and has not moved forward. The Division will keep the Board updated.

Ms. Chambers asked if the Board had any questions and there were none. The Board thanked Ms. Chambers for her time and information provided to the Board.

Resulting from executive session the board made the following motions:

On a motion duly made by Ms. Gruening, seconded by Mr. Holt and approved unanimously, it was

> **RESOLVED to accept the Imposition of two five-hundred dollar ($500) civil fines totaling one thousand dollars ($1,000) for Wells Pharmacy Case No. 2016- 001006.**

On a motion duly made by Ms. Gruening, seconded by Ms. Bell and approved unanimously, it was

> **RESOLVED to accept the Imposition of five-hundred dollar ($500) civil fine for American Specialty Pharmacy Case No. 2016- 001037.**

On a motion duly made by Ms. Gruening, seconded Mr. Henderson and approved unanimously, it was

> **RESOLVED to accept the voluntary suspension of pharmacist license for Cynthia Aguiar Case No. 2017-000092.**

Investigator Howes reviewed the PDMP Report (August 1, 2016-April 30, 2017). Since that last report registered users increased from 1,629 to 2,181 equating to an increase of 34%. The report also included the number of Opiate Agonists prescriptions for each month from August 2016 through April 2017, and searches made by active users for this same time period. Of the 2,181 users registered 1,327 are actively using the PDMP. The number of profile requests within the systems totaled 123,407, 72, 966 pharmacists and 50, 441 prescribers make up that number.

Two letters will be sent out. The first letter will be from the Governor advising all providers what the requirements will be for July registration. The second letter will be from Dr. Jay Butler who is the Chief Medical Officer for the state reiterating the need to register with more details.

Investigator Howes had Chair Holm signed the Board actions and the Board thanked him for his time and information provided.

Break:
Off the record at 10:59 a.m.
Back on the record at 11:13 a.m.

Agenda Item 6 – Annual Report

The Board reviewed, discussed, and worked on the FY 17 Annual Report. As part of the review the Board went over the letter Sara Chambers sent out to all Boards regarding the Annual Report. Ms. Chamber's letter is a reminder to Boards that this report represents the opportunity to reflect on the year's accomplishments and to guide the Board's focus toward upcoming goals and objectives and what report deadline is.

11:24 a.m. Due to technical difficulties with the new lap tops the Board was using Ms. Bellino left the meeting to get IT to assist with the issues. IT was able to fix the problem and the meeting continued.

The Board went over all the components of the report and how to proceed. Chair Holm will write the narrative and any updates. Once the draft of the report is completed the Board will meet via teleconference to adopt the report before Ms. Bellino submits it.

Break for lunch:

Off the record at 12:06 p.m.
On the record at 1:16 p.m.

Agenda Item 7 – Tabled Applications

The Board reviewed additional information requested at the March meeting regarding a technician application. Board member Rich Holt requested more detailed information was satisfied with was submitted and approved the application.

Agenda Item 8 –Regulations

The Board spent the remainder of the afternoon discussing and reviewing several regulations in need of updates, revision, or clarification.

When reviewing **12 AAC 02.107 Prescription drug monitoring program registration.** This regulation establishes fees for registration with the database by a pharmacist who dispenses or a practitioner who prescribes, administers, or directly dispenses a scheduled II, III, or IV controlled substance under the federal law as required under AS 17.30.200. The Board had many questions and requested Ms. Bellino call Investigator Howes to see if he was available to re-join the meeting to discuss this topic.

As requested, at 1:48 p.m. Investigator Howes joined the meeting to answer the Board's questions.
The majority of questions the Board had was pertaining to the amount of fee the division came up with, and how the monies collected go back to the PDMP. Investigator Howes understood that it is set up that the fees collected from all the impacted boards could somehow be credited back. The Board was also concerned that by collecting a fee would it jeopardize any current or future grants. Investigator Howes advised that fees collected would not impact any grants.

Overall the Board's concerns were that the $25.00 fee is slightly high. The Board felt that a $20.00 a year fee should cover expenses. The Board also wanted to know how the fee is determined and would be re-evaluated based on the over and above cost of the grant, and who is going to determine that and when/how. Is the intent to be licensed every two years, and does it need to be more clear as to how this fee is attached to a license, and to know that it is a two year fee of $50.00 or $40.00 and just by paying the fee does not mean you have been registered to the PDMP by just applying for a license. Investigator Howes advised there has been discussion that this fee would be linked to license renewal, and can be done in such a way that the licensee will have to provide documentation that registration of controlled substances has occurred before a license would be renewed.

The Board thanked Investigator Howes for being available to talk this through with the Board.

The Board continued their review and discussion on the other regulations listed on the agenda. The Board had spirited and deliberative discussions regarding changes to the below listed regulations. All confirmed changes will be read into the record when the Board has determined and completed their regulation review.

Break:
Off the record at 3:00 p.m.
Back on the record at 3:19 p.m.

Regulations discussed for possible changes:
12 AAC 52.130 Registration of Pharmacies Located Outside of the State
12 AAC 52.200 Pharmacist-in-Charge
12 AAC 52.210 Review of Pharmacist Intern License Examination
12 AAC 52.240 Pharmacist Collaborative Practice Authority
12 AAC 52.423 Remote Pharmacy License
12 AAC 52. 425 Telepharmacy System for a Remote Pharmacy

Due to the length and complexity of the Board's discussion regarding remote pharmacy and telepharmacy regulations, and changes Mr. Holm is recommending for these two regulations, the Board will continue this discussion on Friday when the board will complete regulation review.

Adam Chesler, PharmD Director of Regulatory Affairs for CardinalHealth participated in the Board's discussion on remote pharmacy and telepharmacy regulations. At Friday's meeting Mr. Chesler will provide feedback to the board on how other states handled similar changes.

On a motion duly made by Mr. Holm, seconded by Ms. Gruening and approved unanimously, it was

RESOLVED to recess the meeting until Friday morning, May 5th at 9:00 a.m.

Off the record at 4:55 p.m.

Friday May 5, 2017

The meeting was called to order by Leif Holm, Board Chair, at 9:00 a.m.

Call to Order/Roll Call

Those present, constituting a quorum of the board, were:

Leif Holm, Pharm D, North Pole- Chair
Rich Holt, Pharm D, Wasilla – Vice Chair
Anne Gruening Public Member, Juneau – Secretary
Phil Sanders RPh, Soldotna
James Henderson, RPh, Soldotna
Lana Bell, RPh, Anchorage

In attendance from the Division of Corporations, Business & Professional Licensing, Department of Commerce, Community and Economic Development were:

Donna Bellino, Licensing Examiner – Juneau

Visitors Present –

Adam Chesler, PharmD - Director, Regulatory Affairs/CardinalHealth - Telephonically

Agenda Item 1 Review Agenda –

The Board reviewed the agenda for Friday, May 5, 2017.

On a motion duly made by Ms. Bell, seconded by Ms. Gruening and approved unanimously, it was

RESOLVED to approve the agenda as is for Friday May 5th.

AGENDA ITEM 1 – Public Comment –

Chair Holm called for public comment at 9:05 a.m. No callers, nor anyone present for public comment.

Agenda Item 2 – MPJE Item Workshop Recap

Mr. Holt provided a brief recap to the Board from the MPJE Item Workshop he and Ms. Bellino attended in March.

Mr. Holt thought it was extremely helpful to have a second person attend to work with. Mr. Holt was the only Board member to attend last year, and it is more difficult to achieve the goals of the MPJE Item Workshop with one person attending and recommends that two people always attend. Mr. Holt also recommended that the Board does not attempt this remotely which is an option and has the Board has done in the past. NABP strongly recommends at least two people from each state board attend this yearly workshop and provides a $1,500.00 travel grant for each member to attend.

Mr. Holt discussed with NABP that the Board has nine regulations that are about to be signed off by the Lt. Governor and in thirty days of signature will go into effect. Mr. Holt wanted to know from NABP how to pull those questions that are on the exam that are related to the regulation changes. NABP advised they can quickly pull questions based on category or key word search and send it to the Board. A Board member or members would have to go through them and determine if the question

is still applicable or not based on the regulation changes. If not, the question can be pulled from the exam so that questions no longer applicable to state regulations remain on the exam. There is a pool of 2,000 questions for the Alaska MPJE exam. With all the changes to the regulations that the Board has is continuing to work on, Mr. Holt suggested that the Board start reviewing all the questions in the pool to ensure they are up to date and accurate. The questions that are no longer up to date can be pulled from the exam quickly. Mr. Holt advised that there are other states that devote time at each meeting to into executive session to review exam questions. The Board could choose a category of questions to review and have NABP pull them for the Board to go over and determine what questions are no longer pertinent.

The Board is in agreement that this should be incorporated into future BOP meetings. Ms. Bellino stated she was very thankful for the experience to attend and what an eye opener it was regarding the importance of language chosen when writing regulations and how that works back to writing regulation questions. Mr. Holt will reach out to NABP to get started with reviewing the pool of exam questions at future BOP meetings.

Agenda Item 3 – New/Old Business

The Board reviewed the August and November Board of Pharmacy dates previously chosen and also had to determine the meeting format. The Board's decision is to travel and meet in person in Anchorage for both meetings.

August 10th & 11th meet in Anchorage
November 30th & December 1st meet in Anchorage

The Board will determine the next round of meeting dates at the August meeting instead of waiting until the November meeting to do it.

Ms. Bellino advised the Board that since SB74 regulations were not ready to review/adopt for this meeting that a teleconference will be scheduled when the regulations are ready for board review.

Ms. Bell has been approved for out-of-state travel to attend NABP's 113th Annual Meeting being held May 20-23 in Orlando, Florida. Ms. Bell will provide a recap to the Board at the August meeting.

The Project Tracking Spreadsheet included with the meeting information has been updated. Ms. Bellino will add the regulations determined to be amended at this meeting.

Wall Certificates were given to Chair Holm for signature.

Agenda Item 4 – Correspondence/Report of Theft or Loss Reports

The Board reviewed correspondence and one Theft/Loss report received since the March meeting.

Break:
Off the record at 10:05 a.m.
Back on the record at 10:15 a.m.

Agenda Item 5 – Regulation Discussion Cont'd from Thursday

The Board continued their regulation review/discussion from Thursday's meeting.

Additional regulations reviewed/discussed:
12 AAC 52.470 Refills
12 AAC 52. 480 Labeling
12 AAC 52.610 Wholesale Drug Distributor License
12 AAC 52. 991 Disciplinary Decision or Conviction Reporting Requirement

Resulting from the Board's regulation review and discussion the following nine regulation amendments were approved.

On a motion duly made by Mr. Holt, seconded by Ms. Gruening and approved unanimously, it was

> **RESOLVED to approve the following regulations changes for submission to Regulation Specialist in preparation for public comment:**

12 AAC 52.120 REVIEW OF PHARMACIST INTERN LICENSE APPLICATION - Currently reads:
(b)(6) submits a completed authorization of release of records on a form provided by the department and signed by the applicant; and
(7) submits a completed Alaska Jurisprudence Intern Practice Questionnaire prepared by the board covering the provision of AS 08.80 and this chapter and 21 U.S.C. 801-847 (Controlled Substances Act).

12 AAC 52.120 REVIEW OF PHARMACIST INTERN LICENSE APPLICATION is amended to read:

(b)(6) submits a completed authorization of release of records on a form provided by the department and signed by the applicant;
(7) submits a completed Alaska Jurisprudence Intern Practice Questionnaire prepared by the board covering provisions of AS 08.80 and this chapter and 21 U.S.C. 801-847 (Controlled Substances Act); and
(8) submits two affidavits from reputable citizens that the applicant has known for at least one year attesting to the applicant's good moral character.

12 AAC 52. 130 REVIEW OF APPLICATION FOR REGISTRATION OF PHARMACIES LOCATED OUTSIDE OF THE STATE - Currently reads:

(b)(4) submits an inspection report or self-inspection report completed within the last two years
(c) A pharmacy located outside the state that ships, mails or delivers prescription drugs more than twice during a 12-month period to individual patients in the state shall register with the board.

Amended to read:
12 AAC 52*.130 REGISTRATION OF PHARMACIES LOCATED OUTSIDE OF THE STATE*
(b) (4) submits a completed self-inspection of the premises questionnaire on a form provided by the department;
(5) submits a copy of the most recent report resulting from an inspection of the pharmacy by the regulatory or licensing agency of the jurisdiction in which the pharmacy is located; and
(6) submits proof satisfactory to the board that the pharmacy maintains its records of prescription drugs dispensed to persons in the state so that the **records are readily retrievable from the records of other prescription drugs dispensed by the pharmacy.**

(c) A pharmacy located outside of the state that ships, mails, or delivers prescription drugs more than twice during a 12-month period into the state shall register with the board.
(d) an out-of-state pharmacy registered with the board under this section shall furnish to the board annually:

1) the location, names and titles of all principal corporate officers and of all pharmacists who are dispensing prescription drugs to residents of the state;

2) a copy of a current valid license, permit, or registration to conduct operations in the jurisdiction in which it is located;
3) a copy of the most recent report resulting from an inspection of the pharmacy by the regulatory or licensing agency of the jurisdiction in which the pharmacy is located;
4) a sworn statement indicating that the pharmacy complies with all lawful directions and requests for information from the regulatory or licensing authority of the jurisdiction in which the pharmacy is licensed; and
5) proof satisfactory to the board that the pharmacy maintains its records of prescription drugs dispensed to persons in the state so that the records are readily retrievable from the records of other prescriptions drugs dispensed by the pharmacy.

(e) a pharmacy located outside of the state that is subject to this section but is not registered with the board under this section may not ship, mail, or deliver prescription drugs into the state and may not advertise its services in the state.
(f) A change in pharmacy ownership shall require the new owner of the pharmacy to apply for a new and separate facility registration in accordance with (b).
(g) A change of pharmacy location or name shall require the pharmacist-in-charge of the pharmacy to apply for a new and separate facility registration in accordance with (b).
(h) The board may, after hearing, deny, revoke, or suspend the registration of a pharmacy located outside of the state and subject to this section if the pharmacy fails to comply with the requirements of this section, AS 17.20.080-AS 17.20.135, or AS 17.30.020-AS 17.30.080, or if the license, permit, or registration of the pharmacy is denied, revoked, or suspended by the licensing or regulatory agency of the jurisdiction in which the pharmacy is located.

12 AAC 52.200 Pharmacists-in-Charge -Currently reads:

(c) A pharmacist designated to replace the pharmacist-in-charge of a pharmacy shall notify the board within 10 days of the designation.

12 AAC 52.200 Pharmacists-in-Charge is amended to read:

(c) A pharmacist designated to replace the pharmacist-in-charge of a pharmacy shall notify the board by submitting the Change of Pharmacy Manager form provided by the department and pay a $50.00 fee within 10 days of the designation.

12 AAC 52 240 PHARMACIST COLLABORATIVE PRACTICE AUTHORITY – Currently reads: (a) A pharmacist planning to exercise collaborative practice authority in the pharmacist's practice by initiating or modifying drug therapy in accordance with a written protocol established and approved for the pharmacist's practice by a practitioner authorized to prescribe drugs under AS 08 must submit the completed written protocol to the board and be approved by the board before implementation.

12 AAC 52.240 PHARMACIST COLLABORATIVE PRACTICE AUTHORITY is amended to read: ***(a) A pharmacist planning to exercise collaborative practice authority in the pharmacist's practice by initiating or modifying drug therapy in accordance with a written protocol to the board, pay a $50 application fee and be approved by the board before implementation.***

12 AAC 52.470 REFILLS is amended by adding new sections to read:

(d) if an original prescription drug order is prescribed as a 30-day supply, the pharmacist may dispense up to a 90-day supply on refills provided that the

(1) patient has completed an initial 30-day supply of the drug;

(2) total quantity of dosage units dispensed does not exceed the total quantity of dosage units authorized by the prescriber on the prescription, including refills;

(3) drug is not a control substance; and

(4) pharmacist is exercising professional judgement.

(e) To indicate that an increased supply shall not be dispensed pursuant to this section, a prescriber may indicate "No change to quantity", or words of similar meaning, on the prescription drug order.

(f) Nothing in this section shall be construed to require a health care service Plan, health insurer, workers' compensation insurance plan, pharmacy benefits manager, or any other person or entity, including, but not limited to, a state program, or state employer, to provide coverage for a drug in a manner inconsistent with a beneficiary's plan benefit.

12 AAC 52. 480 LABELING - Currently reads:

One or more labels containing the following information shall be affixed to every container in which a prescription drug order is dispensed:

1) Name, address, and phone number of the dispensing pharmacy;
2) Unique identification of the prescription drug order;
3) date the prescription drug order is dispensed;
4) initials of the dispensing pharmacist;
5) name of the prescribing practitioner;

6) name of the patient or, if the drug was prescribed for an animal, the species of animal and the name of the owner;
7) direction for use;
8) quantity dispensed
9) appropriate ancillary instructions or cautions;
10) if the prescription drug order is for a schedule II-V controlled substance, the statement "Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed";
11) the name and strength if the actual drug product dispensed; if the drug product dispensed has multiple ingredients, the pharmacist shall provide this information in writing to the patient's agent.

12 AAC 52.480 LABELING is amended to read:

(a) One or more labels containing the following information shall be affixed to every container in which a prescription drug order is dispensed:
1) name, address, and phone number of the dispensing pharmacy;
2) unique identification number of prescription drug order;
3) date the prescription drug is dispensed;
4) initials of the dispensing pharmacist;
5) name of the prescribing practitioner;
6) name of the patient or, if the drug was prescribed for an animal, the species of the animal and the name of the owner;
7) directions for use;
8) quantity dispensed;
9) appropriate ancillary instructions or cautions;
10) if the prescription drug order is for a schedule II-V controlled substance, the statement "Caution: Federal Law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed";
11) the name and strength of the actual drug product dispensed, unless otherwise directed by the prescribing practitioner; and
12) the accepted generic drug name and strength of the drug dispensed; if the drug product dispensed has multiple ingredients, the pharmacist shall provide this information in writing to the patient or the patient's agent.
(b) In addition to section (a), a pharmacy registered with the board as an out-of-state pharmacy shall provide their toll-free number and the hours that the service is available on a label affixed to each container of drugs dispensed to persons in the state.
(1) the telephone service shall be available at least 40 hours a week and at least six days a week.

12 AAC 52.510 SUBSTITUTION – Currently reads: (a) A pharmacist may dispense an equivalent drug product instead of the prescribed drug if

(1) the prescribing practitioner does not hand write or electronically not on the prescription drug order that a specific brand must be dispensed, using language such as "brand medically necessary" or similar wording;
(2) the patient is notified and consents to the substitution;
(3) the equivalent drug product costs the patient less than the prescribed drug product; and
(4) for the drug product actually dispensed, the pharmacist notes on the prescription drug order on of the following:
(A) the drug product's manufacturer or distributor;
(B) national drug code number;
(C) short name code; or
(D) trade name.

12 AAC 52.510 SUBSTITITION is amended to read: ***(a) A pharmacist may dispense an equivalent drug product instead of the prescribed drug if***

(1) the prescribing practitioner does not indicate on the prescription drug order that a specific brand must be dispensed using language such as "brand medically necessary", "dispense as written –DAW', "do not substitute" or other similar wording.
(2) the patient is notified and consents to the substitution.
(3) the equivalent drug product costs the patient less than the prescribed drug product; and
(4) for the drug product actually dispensed, the pharmacy record shall contain one of the following:
(A) the drug products manufacturer or distributor;
(B) national drug code number;
(C) short name code; or
(D) ***trade name***

12 AAC 52.610 WHOLESALE DRUG DISTRIBUTOR LICENSE – Currently reads:

(c) Within 30 days of a change in a facility manager, the new facility manager must meet the requirements of (a)(4) and (6) of this section.

12 AAC 52.610 WHOLESALE DRUG DISTIBUTOR LICENSE - is amended to read:
Within 30 days of a change in facility manager, the new facility manager must submit the Change of Pharmacy Manager form provided by the department, pay a $50 fee and meet the requirements of (a)(4) and (6) of this section.

12 AAC 52.991 DISCIPLINARY DECISION OR CONVICTION REPORTING REQUIREMENT – Currently reads: A licensee shall report in writing to the board any disciplinary decision or conviction, including conviction of a felony or conviction of another crime that affects the applicant's or licensee's ability to practice competently and safely, issued against the licensee not later than 30 days after the date of the disciplinary decision or conviction.

12 AAC 52.991 DISCIPLINARY DECISION OR CONVCTION REPORTING REQUIREMENT – is amended to read: ***A licensee or facility licensed by the board under 12 AAC 52.010 shall report in writing to the board any disciplinary decision or conviction, including conviction of a felony or conviction of another crime that affects the facility, employee of the facility, or licensee's ability to practice competently and safely, issued against the facility, employee of the facility or licensee not later than 30 days after the date of the disciplinary decision or conviction.***

The Board continued their spirited and deliberative discussion on **12 AAC 52.423 Remote Pharmacy License and 12 AAC 52.425 Telepharmacy System for a Remote Pharmacy.** Resulting from the Board's discussion on these regulations more work is needed and changes identified will be added to the regulations for the Board to review at the next BOP meeting or at the teleconference that will be scheduled to review/adopt SB 74 regulations.

The Board decided to work past the noon end time to have a chance to review and discuss possible changes regarding pharmacy technicians. The Board requested a short break.

Break:
Off the record at 11:50 a.m.
Back on the record at 12:12 p.m.

The Board spent the remainder of the meeting discussing pharmacy technicians and the best way to proceed given how the role of the technician is rapidly changing in the pharmacy profession.

The Board looked at the current licensing requirements and the impact of possibly adding a "nationally certified" technician category. There are pro's and con's to establishing a "type" of technician license from how it currently is which only has the one category for a Pharmacy Technician.

The Board had spirited and deliberative discussion on this topic and many opinions were given. Due to the large scope of this topic and varying opinions, Mr. Holt will work up the changes agreed upon and the Board will review what those changes look like at the August meeting.

On a motion duly made by Mr. Holm, seconded by Ms. and approved unanimously, it was

RESOLVED to adjourn the meeting.

The board adjourned at 1:07 p.m.

Respectfully Submitted:

Donna Bellino

Donna Bellino
Licensing Examiner

Approved:

Leif Holm, PharmD., Chair
Date: 8/11/17